FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression

March 5, 2019 -- The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news